Global Cardiovascular Drugs Market

Cardiovascular Drugs Market Size, Share, Growth Analysis, By Drug Type(Antihypertensive, Anticoagulants, Antihyperlipidemic, Antiplatelet Drugs), By End User(Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35D2041 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 64 | Figures: 75

Cardiovascular Drugs Market News

  • In February 2022, the Food and Drug Administration (FDA) expanded approval of empagliflozin (Jardiance) for use in adults with heart failure (HF), regardless of ejection fraction, to reduce the risk of cardiovascular death and HF hospitalization. The drug was approved in August 2021 to reduce the risk of cardiovascular death and HF hospitalization in adults with HF with reduced ejection fraction.
  • In May 2022, Amgen reported positive data from the Phase 2 OCEAN(a)-DOSE clinical study evaluating olpasiran (formerly AMG 890) in 281 adult patients with lipoprotein(a), or Lp(a), levels greater than 150 nmol/L. disclosed evidence of atherosclerotic cardiovascular disease (ASCVD). Olpsiran is a small interfering RNA designed to reduce the body's production of apolipoprotein (a), an important component of Lp (a) that is associated with an increased risk of cardiovascular events.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cardiovascular Drugs Market size was valued at USD 162.63 billion in 2022 and is poised to grow from USD 169.98 billion in 2023 to USD 242.10 billion by 2031, growing at a CAGR of 4.52% in the forecast period (2024-2031).

Global cardiovascular drugs market is highly competitive with the presence of local as well as global companies. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of global cardiovascular drugs market. 'Pfizer Inc.', 'Novartis AG', 'AstraZeneca PLC', 'Merck & Co., Inc.', 'Sanofi S.A.', 'Bristol-Myers Squibb Company', 'Boehringer Ingelheim GmbH', 'Bayer AG', 'Abbott Laboratories', 'Johnson & Johnson', 'Eli Lilly and Company', 'Amgen Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Daiichi Sankyo Company, Limited', 'Gilead Sciences, Inc.', 'GlaxoSmithKline plc', 'Mylan N.V.', 'Takeda Pharmaceutical Company Limited', 'Astellas Pharma Inc.', 'AbbVie Inc.'

According to WHO, 60% to 85% of the population is sedentary. According to the CDC, approximately 31 million Americans over the age of 50 lead a sedentary lifestyle, and only one in four US adults receive recommended physical activity. This factor increases market growth.

Obesity and high cholesterol levels increase the risk of cardiovascular disease. The use of emergency medicine is commonly seen in hospitals, which has shown great potential for market growth. A large number of patients receive personal care for chronic conditions, which proves to be a steady seller for the market and continues to generate revenue returns. The use of cardiovascular drugs has also increased the prevalence of hypertension. There is a high demand for blood thinners in the market due to the increasing incidence of cardiovascular diseases. The increasing life expectancy of the elderly population has increased the demand for cardiovascular drugs. The increasing prevalence of cardiovascular disease in children has boosted the sales of these emergency drugs. Hypertensive drugs are difficult to discontinue, which helps maintain supply and demand.

On the basis of region, global cardiovascular drugs market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. North America has witnessed the highest growth in the global cardiovascular drugs market due to the high prevalence of cardiovascular disorders in the population. Due to increasing industrialization and the popularity of fast food, the prevalence of high blood pressure and other heart diseases has increased. People's sedentary lifestyle choices, along with poor eating habits, have increased the risk of cardiovascular disease, increasing the demand for these treatments.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Prescription Drugs Market
Buy Now GET FREE SAMPLE
Cardiovascular Devices Market
Buy Now GET FREE SAMPLE
Anti Obesity Drugs Market
Buy Now GET FREE SAMPLE
Erectile Dysfunction Drugs Market
Buy Now GET FREE SAMPLE
Muscle Relaxant Drugs Market
Buy Now GET FREE SAMPLE
Pharmaceuticals Market
Buy Now GET FREE SAMPLE
Psychedelic Drugs Market
Buy Now GET FREE SAMPLE
Over The Counter Drugs Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Cardiovascular Drugs Market

Report ID: SQMIG35D2041

$5,300
BUY NOW GET FREE SAMPLE